CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 167 enrolled
Drug / intervention
Pegylated Liposomal Doxorubicindrug
Likely dose
Pegylated Liposomal Doxorubicin 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00736333
NCT00736333N/ACompleted
CompareCT.gov

Observational Program of Caelyx in MBC - Prevention and Treatment of PPE and Infusion Reactions

Merck Sharp & Dohme LLC·observational·Posted Aug 15, 2008·Updated Nov 5, 2014

In Brief

An observational study evaluating Pegylated Liposomal Doxorubicin for Breast Neoplasm. Completed, enrolled 167 participants.

Detailed Summary

This is a study to evaluate the safety and tolerability of Caelyx used for the treatment of metastatic breast cancer (MBC), focusing on infusion reaction and palmar-plantar erythrodysesthesia (PPE).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasm
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2008
Enrollment StartNov 1, 2006
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 17.9 years ago

Interventions

Pegylated Liposomal Doxorubicindrug

Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m\^2, given for up to 6 cycles